Abbott Laboratories Completes Acquisition of Exact Sciences, Strengthens Market Position

AI Summary

On March 23, 2026, Abbott Laboratories (NYSE: ABT) completed the acquisition of Exact Sciences, positioning itself as a leader in the cancer screening and diagnostics market. This acquisition adds a significant growth vertical to Abbott's high-single-digit growth outlook and aims to address a $60 billion U.S. market focused on cancer screening and precision oncology diagnostics. Following the acquisition, Exact Sciences has become a wholly-owned subsidiary of Abbott Laboratories. This strategic move highlights Abbott's commitment to enhancing early cancer detection and personalized treatment options.